Table 1 Impact of NEFM on overall survival (OS) in Pan-cancer RNA-seq in Kaplan–Meier plotter
From: NEFM DNA methylation correlates with immune infiltration and survival in breast cancer
Cancers | No. of patients | MST (OS,Month) | HR | p | |
|---|---|---|---|---|---|
NEFM high expression | NEFM low expression | ||||
Kidney renal clear cell carcinoma | 530 | 36.57 | 52.23 | 1.49 | 0.031 |
Lung adenocarcinoma | 501 | 40.3 | 54.4 | 1.55 | 0.0046 |
Stomach adenocarcinoma | 371 | 25.97 | 56.2 | 1.5 | 0.025 |
Bladder carcinoma | 405 | 31.37 | 42.33 | 1.35 | 0.047 |
Head–neck squamous cell carcinoma | 499 | 37.8 | 66.73 | 1.43 | 0.012 |
Ovarian cancer | 373 | 43.8 | 45.47 | 1.37 | 0.027 |
Sarcoma | 259 | 36.27 | 82.13 | 1.96 | 0.0011 |
Pancreatic ductal adenocarcinoma | 177 | 22.03 | 15.57 | 0.57 | 0.011 |
Cervical squamous cell carcinoma | 304 | 29.3 | 68.4 | 1.52 | 0.13 |
Lung squamous cell carcinoma | 495 | 44.87 | 71.1 | 1.33 | 0.059 |
Rectum adenocarcinoma | 502, | NA | NA | 3.17 | 0.098 |
Thyroid carcinoma | 502 | NA | NA | 0.36 | 0.053 |
Pheochromocytoma and paraganglioma | 178 | NA | NA | 0.18 | 0.035 |
Uterine corpus endometrial carcinoma | 543 | 103.73 | 51.6 | 0.7 | 0.097 |